-
GDC-0941: Translating PI3K/Akt Biology into Strategy
2026-09-15
A translational framework for using GDC-0941 to interrogate PI3K/Akt-dependent resistance, cancer stem cell phenotypes, and treatment response across HCC and HER2-amplified models.
-
Tariquidar: A Causal Probe of P-gp Chemoresistance
2026-09-15
Tariquidar (XR9576) provides a powerful way to test whether mechanically induced chemoresistance depends on functional P-glycoprotein activity. This article translates new high-viscosity tumor-microenvironment findings into a controlled assay strategy for drug resistance research.
-
Tariquidar (XR9576) in P-gp Chemoresistance Assays
2026-09-14
Tariquidar (XR9576) provides a practical way to separate P-glycoprotein-driven drug efflux from viscosity-induced chemoresistance. This workflow combines transporter inhibition with mechanical microenvironment controls, fluorescence assays, and troubleshooting safeguards against BCRP and vehicle-related confounding.
-
Ethacridine Lactate Monohydrate in Ectoderm Assays
2026-09-14
Ethacridine lactate monohydrate can support contamination-aware stem-cell and biochemical workflows without being confused with a differentiation reagent. This article connects its formulation and antiseptic use with the YAP–TEAD super-enhancer framework, emphasizing controls, assay interpretation, and practical limitations.
-
Ionizable Drugs for Intracellular siRNA Delivery
2026-09-13
The reference study introduces drug-rich nanoparticles in which ionizable fulvestrant analogs replace conventional ionizable lipids to co-formulate small interfering RNA and a small-molecule drug. Formulation-dependent reporter knockdown and delivery of cyclin E1 siRNA to drug-resistant breast cancer cells support this platform as a way to coordinate pharmacological and genetic interventions.
-
Hypoxia–S100A10 Signaling in Glioblastoma
2026-09-12
A 2025 study identifies hypoxia-induced S100A10 as a functional link between glioblastoma adaptation, glycolytic activity, proliferation, and temozolomide resistance. By combining public datasets with molecular, metabolic, cell-cycle, and apoptosis assays, the work positions PI3K–AKT signaling as a central mechanism connecting the hypoxic tumor environment to treatment failure.
-
BKT140 (BL-8040) CXCR4 Research Workflows
2026-09-12
BKT140, also called BL-8040, enables mechanism-focused studies of CXCL12/CXCR4 signaling across tumor migration, apoptosis, and hematopoietic cell trafficking. This practical guide connects formulation, chemotaxis, tumor-microenvironment, and stem-cell mobilization workflows while showing how receptor imaging concepts can strengthen assay interpretation.
-
PAD4-IN-2 TFA: From Target to Assay
2026-09-11
PAD4-IN-2 TFA is a tumor-targeted PAD4 inhibitor designed to suppress H3 citrullination and NET biology. This guide focuses on translating its PBA-mediated selectivity into rigorous biochemical, cellular, and in vivo cancer research assays.
-
ORAI2 Drives Early Postirradiation Salivary Fibrosis
2026-09-11
This study identifies ORAI2-dependent store-operated calcium entry as an early driver of radiation-induced salivary gland fibrosis and connects it mechanistically to JNK, NFAT1, and TGF-β1 signaling. Its findings position calcium-pathway inhibition as a way to investigate both fibrotic remodeling and functional hyposalivation after radiotherapy.
-
Bestatin (Ubenimex): From Inhibition to Translation
2026-09-10
Bestatin (Ubenimex) is more than a conventional aminopeptidase inhibitor: it is a mechanistic probe for connecting zinc-aminopeptidase biology with cancer research, apoptosis assay design, and multidrug resistance studies. This article examines how its biochemical profile, structural precedent, and practical handling requirements can support more disciplined translational workflows.
-
Verteporfin (A8327): Reliable Assay Workflows
2026-09-10
Learn how Verteporfin (SKU A8327) can improve the design and interpretation of cell viability, cytotoxicity, apoptosis, and autophagy experiments. This scenario-based guide separates light-dependent effects from light-independent biology and provides practical concentration, storage, and control recommendations.
-
PBA-Targeted PAD4 Inhibitors Block Tumor NETs
2026-09-09
This study developed phenylboronic acid-modified PAD4 inhibitors designed to preferentially target tumor-associated biology while suppressing the PAD4–H3cit–NET pathway in neutrophils. The lead compound 5i reduced tumor growth and lung metastasis in mouse models, highlighting a strategy for improving PAD4 inhibitor selectivity without relying solely on direct tumor-cell killing.
-
Neuritin, ER Stress, and Early Brain Injury After SAH
2026-09-09
This study identifies endoplasmic reticulum stress-related inflammatory signaling as a mechanistic link between subarachnoid hemorrhage, neuroinflammation, and neuronal apoptosis. Its central finding is that Neuritin overexpression suppresses three NF-κB-associated ER stress pathways, providing a framework for interpreting neuroprotective interventions in early brain injury.
-
FGF19-ELF4 Signaling Drives Colorectal Cancer Metastasis
2026-09-08
This study identifies an FGF19–ELF4–FGFR4/SRC signaling circuit that links an extracellular growth-factor signal to transcriptional control of colorectal cancer metastasis. Its combination of clinical profiling, functional models, RNA sequencing, promoter assays, and chromatin immunoprecipitation provides a mechanistic basis for testing dual FGFR4 and SRC inhibition.
-
Medroxyprogesterone Acetate: A Mechanistic Assay Guide
2026-09-08
Medroxyprogesterone acetate (MPA) is more than a progestin stimulus: it is a useful mechanistic probe for separating progesterone receptor, glucocorticoid receptor, renal, reproductive, and neural responses. This guide integrates MPA assay design with a recent multi-omics study of endometrial stromal cell senescence to improve causal interpretation.